Safety, efficacy, and acceptability of adv7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis

HIGHLIGHTS

• who: Aurélia Bertholet-Thomas from the Centre de Référence des Maladies Rénales Rares-Néphrogones- ORKiD, Bron, France have published the research: Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis, in the Journal: (JOURNAL)
• what: This work evaluates safety and efficacy of ADV7103 during 24 months. The aim of the study was to evaluate the longterm safety of ADV7103 as measured by the occurrence of adverse events (AEs).
• how: Clinical interpretation of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.